Aptose biosciences inc. (APTO)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17Jun'17
Expenses:
Revenue

-

-

-

-

-

-

-

-

-

0

0

Research and development

5,934

5,253

4,751

3,491

3,340

4,184

3,591

7,818

3,140

1,390

1,088

General and administrative

5,900

2,631

2,276

2,855

2,260

2,141

2,020

2,511

3,702

1,319

1,393

Operating expenses

11,834

7,884

7,027

6,346

5,600

6,325

5,611

10,329

6,842

-

-

Other income (expense):
Interest income

323

167

187

128

92

85

80

74

44

-

-

Foreign exchange gains/( losses)

-15

8

-4

0

2

-21

0

-7

-16

-

-

Total other income

308

175

183

128

94

64

80

67

28

-

-

Net loss

-11,526

-7,709

-6,844

-6,218

-5,506

-6,261

-5,531

-10,262

-6,814

-

-

Other comprehensive loss:
Unrealized gain/(loss) on securities available-for-sale

-

5

-5

9

9

-

9

-4

-2

-

-

Total comprehensive loss

-11,526

-7,704

-6,849

-6,209

-5,497

-6,264

-5,522

-10,266

-6,816

-

-

Basic and diluted loss per common share (in dollars per share)

-0.15

-0.13

-0.12

-0.13

-0.14

-0.17

-0.16

-0.30

-0.23

-

-

Weighted average number of common shares outstanding used in the calculation of (in thousands) Basic and diluted loss per common share (in shares)

76,227

58,866

55,454

46,474

39,846

35,985

34,587

33,950

29,042

-

-

Operating Expenses

-

-

-

-

-

-

-

-

-

2,709

2,481

Finance expense (note 9)

-

-

-

-

-

-

-

-

-

0

0

Finance income (note 9)

-

-

-

-

-

-

-

-

-

69

40

Net finance income

-

-

-

-

-

-

-

-

-

69

40

Net loss and comprehensive loss for the period

-

-

-

-

-

-

-

-

-

-2,640

-2,441

Basic and diluted loss per common share (in dollars per share)

-

-

-

-

-

-

-

-

-

-0.11

-0.11

Weighted average number of common shares outstanding used in the calculation of basic and diluted loss per common share (000s) note 6(b) (in shares)

-

-

-

-

-

-

-

-

-

24,061

21,309